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Regulation of the dystrophin-
associated glycoprotein complex 
composition by the metabolic 
properties of muscle fibres
saleh omairi1,2, Kwan-Leong Hau3,4, Henry Collins-Hooper1, Charlotte scott3,4, 
sakthivel Vaiyapuri5, Silvia torelli3,4, Federica Montanaro3,4, Antonios Matsakas  6 & 
Ketan patel1
the dystrophin-glycoprotein complex (DGC) links the muscle cytoskeleton to the extracellular matrix 
and is responsible for force transduction and protects the muscle fibres from contraction induced 
damage. Mutations in components of the DGC are responsible for muscular dystrophies and congenital 
myopathies. Expression of DGC components have been shown to be altered in many myopathies. In 
contrast we have very little evidence of whether adaptive changes in muscle impact on DGC expression. 
In this study we investigated connection between muscle fibre phenotype and the DGC. Our study 
reveals that the levels of DGC proteins at the sarcolemma differ in highly glycolytic muscle compared to 
wild-type and that these changes can be normalised by the super-imposition of an oxidative metabolic 
programme. Importantly we show that the metabolic properties of the muscle do not impact on the 
total amount of DGC components at the protein level. Our work shows that the metabolic property of a 
muscle fibre is a key factor in regulating the expression of DGC proteins at the sarcolemma.
Skeletal muscle has an elaborate network of proteins responsible for translating the shortening of the sarcomeres 
into force capable of moving bones to permit locomotion. Furthermore it protects the muscle fibre from damage 
during contraction1. These proteins, collectively known as the dystrophin-glycoprotein complex (DGC), link the 
cytoskeleton to laminin in the extracellular matrix (ECM)1,2. Dystrophin, the first identified member of this com-
plex, is a large intracellular protein composed of four functional units (i.e. N-terminus acting binding segment, 
spectrin repeats, cysteine rich region and the C-terminal portion). Its cysteine rich region binds the transmem-
brane protein β-Dystroglycan (β-DG). α-DG, an extracellular protein, binds β-DG on the surface of the myofibre. 
α-DG directly binds a number of ECM component including Laminin and collagen IV in the basal lamina as well 
as being involved in indirect interactions with interstitial matrix proteins including collagen I (reviewed in3). 
The DGC also contains the members of the Sarcoglycan (SG) family of transmembrane proteins and other com-
ponents (reviewed in4). Mutations in almost any of the DGC genes result in muscle disease e.g. mutations in 
dystrophin lead to Duchenne and Becker Muscular Dystrophy (DMD/BMD)5, mutations in DG and SGs lead to 
a variety of Limb-Girdle Muscular Dystrophies and other pathologies6,7.
The relationship between muscle and the ECM in a disease context is of upmost importance as it has clinical 
implications. Fibrosis is a key feature of DMD and other myopathies3,8. Furthermore a longitudinal study of 
DMD patients concluded that endomysial fibrosis was the only myopathologic parameter that significantly cor-
related with poor motor outcome9 and numerous strategies have been developed to control this feature in order 
to improve clinical features of this disease10. However, the treatments based on controlling fibrosis in neuromus-
cular diseases must also consider the normal function of connective tissue in maintaining muscle fibre function 
and survival. It is well known that there is a correlation between fibre type and propensity to undergo necrosis 
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in DMD; with fast fibres being preferentially affected in DMD11. As fibres in DMD are thought to be damaged 
by contraction mediated damage12 and that the fast fibres these are the ones with the least amount of endomysial 
ECM it is worthy of contemplation where increasing the support nature of the endomysium without evoking a 
fibrotic reaction may confer fibre robustness.
Skeletal muscle is an adaptable tissue which changes in terms of composition and mass in reaction to mechani-
cal, electrical and chemical stimuli13. It is important to comprehend that muscle responds to stimuli by modifying 
both its contractile elements (muscle fibres) and invariably all other tissue components including the blood sup-
ply and ECM. This is exemplified by the phenotype of mice lacking the TGF-ß family protein Myostatin (Mstn), a 
member of the TGF-ß family of secreted proteins. Myostatin is a potent inhibitor of muscle development and oxi-
dative metabolism. Loss of function mutation in the mouse Mstn gene leads not only to hypertrophic/glycolytic/
fast contracting fibres14,15 but also to a decrease in blood vessels and significantly lower levels of ECM components 
compared to wild-type (WT)16. Changes in the ECM of Mstn−/− mice could be attributed to either (1) muscle 
fibre enlargement not being accompanied by a commensurate rise in ECM synthesis, or (2) an adaptive change 
to harmonise ECM to the physiology of muscle. In support of the latter, numerous investigations have suggested 
that fast/glycolytic contracting muscle fibres that tend to be larger in cross sectional area are surrounded by less 
ECM than slow/oxidative contracting fibres17,18.
Several studies have shown that the DGC and ECM undergo profound changes in organisation in a disease 
context19,20. Yet few have examined the impact of physiological adaptation of muscle on the force transduction 
apparatus. Here we used two innovations to address the dearth of knowledge in this field. The first is an allelic 
series that differ in their metabolic properties of muscle fibres21. The series was made by using the Mstn−/− back-
ground as well as the progeny after crossing it with a line expressing Estrogen-related receptor gamma (Errγ), a 
master regulator of oxidative metabolism. Errγ is a transcription factor expressed at elevated levels in slow muscle 
and in tissues with high oxidative metabolism levels. Here it supports mitochondrial activity and biogenesis22,23. 
We have shown that over-expression of Errγ on the myostatin null background results in hypertrophic fibres that 
express MHCIIB and yet robustly express Succinate Dehydrogenase (SDH), a marker of oxidative metabolism. 
This contrasts with the hypertrophic fibres of the myostatin null mouse which tend to express MHCIIB and are 
glycolytic. These two models facilitate comparison of morphological characteristics (i.e. the DGC and ECM) 
between fibres with the same contraction profile (i.e. MHC composition) yet which differ in their metabolic status 
(i.e. oxidative versus glycolytic). Second is the application of semi-quantitative immunofluorescence methods that 
allow the investigator to define the amounts of sarcolemma components and relate this to fibre phenotype24,25. The 
present investigations reveals that fibre type affects the levels of DGC and ECM components. Secondly, sarcolem-
mal levels of all DGC proteins investigated were higher in WT muscle compared to that from the hypertrophic 
Mstn−/−. Lastly we provide evidence that the amount of DGC at the sarcolemma were elevated in Mstn−/− fibres 
following the overexpression of Estrogen Related Receptor Gamma (Erry) (Mstn−/−/ErrγTg/+) which imparts a 
programme of oxidative metabolism. The results presented show that the metabolic programme of muscle is a 
factor in the formation of the DGC and ECM. Finally, we show that the amount of protein found at the fibre mem-
brane is not related to the total amount present in the fibre. These results imply that mechanisms that facilitate 
protein shuttling are important in the development of the force transduction apparatus.
Results
Quantification of inter-fibre collagen in wild-type mouse skeletal muscle. By means of cryo-scan-
ning electron microscopy, our previous work demonstrated that the endomysium of the Mstn−/− mouse is thinner 
in comparison to sex and age- matched wild-type mice (WT)16. Additionally we have shown that collagen I and 
IV are deposited at higher levels between MHCIIB− relative to between MHCIIB+ fibres, a relationship that held 
true in both WT and Mstn−/− muscles16. Here, we used florescence microscopy-based techniques to determine 
how they compared to more laborious electron microscopic approaches to quantify the ECM content of skeletal 
muscle. Using these techniques, we firstly assessed the levels of collagen IV as well as the endomysium thickness 
domain in the between MHCIIB− fibres relative to MHCIIB+ fibres of WT mice. (Note: It was not possible per-
form double immunofluorescence for MHCIIB and collagen IV due to the availability of resolving secondary 
antibodies. Therefore, serial sections were individually stained for the two markers and MHCIIB+ fibres marked 
on the collagen profile (also the case for laminin profiling). Individual staining of MHCIIB, MHCIIA and MHCI 
are shown in Supplementary Figs 1–3. For DGC components, composite images are presented with simultaneous 
staining of sarcolemma protein and MHCIIB expression.) Measurements were made from three muscles with 
differing metabolic profiles as well as MHC distribution (Extensor Digitorum Longus (EDL), soleus, deep and 
superficial portions of the tibialis anterior (TA) muscle). In these muscles the contraction speed based on MHC 
expression, going from fastest to slowest, observes the following order: superficial TA, EDL, deep TA, soleus. In 
each case investigations were made in four non-overlapping regions. Measurement of both fluorescence signal 
intensity and thickness in wild type muscles indicated that there was more collagen IV between MHCIIB− fibres 
compared to MHCIIB+ fibres (Fig. 1A–C, note that WT soleus did not contain any MHCIIB+ fibres), a finding 
that is in agreement with our previous findings using electron microscopy16.
Impact of Mstn−/−/Errγtg/+ on inter-fibre collagen. We next analysed Mstn−/− muscles by fluorescence 
microscopy. Immunolabeling revealed an general reduction in collagen IV around the fibres. Like our findings 
with cryo-electron microscopy, immunofluorescence staining corroborated that the variance in collagen IV levels 
between MHCBII− and MCHBII+ fibres is not influenced by the genetic deletion of myostatin (Fig. 1A–C). These 
results indicate that the deletion of myostatin results in an overall decrease in collagen IV levels that similarly 
affects MHCBII+ and MCHBII− fibres.
Given the excellent correlation between electron microscopy and fluorescence microscopy quantifications, we 
used immunofluorescence to assess the impact of the super-imposition of an oxidative programme on collagen IV 
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deposition in the Mstn null background (Mstn−/−/ErrγTg/+). We found that forced expression of Errγ normalised 
collagen IV levels in Mstn−/− mice levels that were indistinguishable from WT levels, irrespective of MHCIIB 
expression (Fig. 1A–C). Of note, Errγ over-expression on the Mstn null background did not correct the aberrant 
presence of MHCBII+ fibres in the soleus muscle. Expression of an interstitial component of the ECM, collagen 
I, showed the same pattern as collagen IV (a basal lamina protein) with regards to MHCIIB expression and gen-
otype (Supplementary Fig. 1).
Relationship between DGC and laminin and Mstn−/−/Errγtg/+ on skeletal muscle. We next 
examined intracellular, membrane-associated and extracellular components of the DGC that link the myofibre 
cytoskeleton to the collagens with a view of establishing a relationship between expression levels, fibre size and 
metabolic activity mediated in the Mstn−/−/ErrγTg/+. To that end we profiled the expression of dystrophin as an 
intracellular component, β-dystroglycan (βDG), four sarcoglycans (SG, α, β, γ and δ) as representatives of mem-
brane associated polypeptides as well as α-dystroglycan (αDG) and laminin as extra-cellular entities in the EDL, 
soleus and TA muscles of the three cohorts.
Our study revealed that amount of these proteins in relation to MHCIIB expression and genotype could be 
categorised into two groups. Group 1 consisted of proteins where the levels in relation to MHCIIB expression and 
genotype were like to collagens I and IV. This group consisted of dystrophin (Fig. 2), α and βDG (Supplementary 
Fig. 5 and Fig. 3), α and γSG (Fig. 4 and Supplementary Fig. 6) as well as laminin (Fig. 5). Expression of Group 1 
proteins in MHCIIB− fibres was greater, (assessed by intensity measures and thickness) compared to MHCIIB+ 
fibres in WT muscle (panels B and C in Figs 2–5, 5D and Supplementary Figs 5 and 6). Secondly, Group 1 protein 
expression was lower in Mstn−/− fibres when compared to their wild-type MHCIIB−/MHCBII+ counterparts 
(panels B and C in Figs 2–5 and Supplementary Figs 5 and 6). Finally, super-imposing oxidative metabolism 
through Errγ expression on the Mstn−/− background resulted in major change in Group 1 proteins levels. 
Figure 1. Collagen IV profiles in WT, Mstn−/− and Mstn−/−/ErrγTg/+ mouse muscle. (A) Expression of collagen 
IV in relation to MHC fibre type. Serial sections processed with an anti-MHCIIB antibody to identify MHCIIB− 
and MHCIIB+ fibres (see Supplementary Figures). Representative MHCIIB− indicated with yellow stars and 
MHCIIB+ fibres by white stars. Expression of collagen IV was more robust in ECM between two MHCIIB− 
fibres (yellow arrow) compared to that between MHCBII+ fibres (white arrows) in wild type muscle. The same 
relationship albeit at lower levels was noted in Mstn−/− muscle. Expression levels were increased in Mstn−/− by 
Errγ in ECM between MHCIIB− (yellow arrows) as well as MHCIIB+ (white arrows) compared to Mstn−/− 
fibres. (B) Intensity of collagen IV expression quantified by setting standard value of 1 for the level between 
MHCIIB− fibres from WT mice. (C) Collagen IV expression also quantified in terms of thick domain. n = 30 
from each cohort. *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical analysis performed by one-way ANOVA 
followed by Bonferroni correction of multiple comparisons.
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Mstn−/−/ErrγTg/+ MHCIIB− and Mstn−/−/ErrγTg/+ MHCIIB+ fibres showed higher levels of expression than their 
Mstn−/− counterparts. Furthermore in many cases these reached levels displayed by WT fibres (panels B and C in 
Figs 2–5 and Supplementary Figs 2, 5 and 6).
However, the expression of β and δSG failed to follow the trend of Group 1 proteins. Therefore, these were 
assigned to Group 2 molecules. Group 2 proteins like Group 1, Group 2 polypeptides displayed greater expres-
sion in MHCIIB− fibres in comparison to MHCIIB+ fibres (panels B and C in Fig. 6, Supplementary Fig. 7 and 
graphically presented in Fig. 5D). Nevertheless, the expression of Group 2 proteins was greater in Mstn−/− fibres 
in comparison to their MHCIIB−/MHCBII+ counterparts derived from WT muscles (panels B and C in Fig. 6 and 
Supplementary Fig. 7). Lastly our study showed that the Group 2 protein expression in Mstn−/− fibres was largely 
unaffected by the expression of Errγ (panels B and C in Fig. 6 and Supplementary Fig. 4).
Impact of Mstn−/−/Errγtg/+ on total transcript level and muscle protein for key components of 
the DGC. Having shown that levels of components of the DGC present at the sarcolemma vary in the three 
mouse strains, we examined whether this reflected the amount of transcript or the total amount of a specific 
protein in muscle. To that end we examined their levels in the soleus muscle as it displayed strain dependent 
variations at the sarcolemma for most of the molecules. We found that at the transcript level, there was good cor-
relation between amounts of RNA molecules for Dystrophin, DG and βSG to their abundance at the sarcolemma 
in the soleus muscle from the three stains e.g. levels of dystrophin transcript and the protein at the sarcolemma 
were higher in WT and Mstn−/−/ErrγTg/+ compared to Mstn−/− (Fig. 7). Next, we investigated the total amount 
of a subset of DGC proteins in the soleus to determine whether this reflected the amount of transcript and its 
abundance at the sarcolemma. We found that there was no correlation between total amount of Dystrophin, βDG 
or βSG and their abundance at the sarcolemma (Fig. 7). The level of expression of these three proteins was similar 
among all three strains. By contrast, levels of αDG were significantly decreased in Mstn−/− and Mstn−/−/ErrγTg/+ 
Figure 2. Dystrophin profiles in WT, Mstn−/− and Mstn−/−/ErrγTg/+ mouse muscle. (A) Immunofluorescence 
profile of Dystrophin in relation to MHC fibre type. MHCIIB expression in red. Representative MHCIIB− fibres 
are indicated by yellow stars and MHCIIB+ fibres by white stars. Expression of Dystrophin was stronger in ECM 
between two MHCIIB− fibres (yellow arrow) compared to between MHCBII+ fibres (white arrows) in wild type 
muscle. Same relationship albeit at lower levels in Mstn−/− expression between MHCIIB− fibres and MHCIIB+ 
fibres. Expression increased in Mstn−/− by Errγ in ECM between MHCIIB− (yellow arrows) as well as between 
MHCIIB+ (white arrows) fibres compared to those from Mstn−/− mice. (B) Expression of Dystrophin quantified 
by intensity by setting standard value of 1 for the level between MHCIIB− fibres from WT mice. (C) Dystrophin 
expression quantification in terms of thickness. n = 30 for each cohort. *p < 0.05, **p < 0.01, and ***p < 0.001. 
Statistical analysis performed by one-way ANOVA followed by Bonferroni correction of multiple comparisons.
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samples compared to wild type, in agreement with transcript and immunohistochemical finding. Interestingly, 
αDG levels were assayed using the IIH6 antibody that only recognises the mature, fully glycosylated form of 
αDG, that is normally present at the membrane. Therefore, these results indicate that the total amount of DGC 
proteins in muscle as detected by Western blot analysis does not vary with muscle metabolism. However, their 
transcription and localisation to the sarcolemma are affected.
Discussion
Our results firstly show that fibre type, specifically MHCIIB expression, effects levels of sarcolemmal DGC pro-
teins. Secondly, we show that the Mstn phenotype alters the abundance of DGC proteins at the sarcolemma. Most 
importantly we showed that initiation of a programme that drives oxidative phosphorylation in muscle was able 
to reverse the changes of membrane levels for many DGC components in Mstn−/− muscle. We show that DGC 
and ECM components can be divided into two groups. Group I (collagen I, IV, dystrophin, α and βDG, α and 
γSG, laminin) proteins were present at higher at the sarcolemma in wild-type fibres than those from Mstn−/− 
mice for a specific MHCII isoform. However, in Group 2 (ß and δSG) this relationship is reversed.
The development of easy to use techniques have now enabled investigators to examine the association between 
metabolism and the ECM and metabolism at single fibre resolution. In this study we deployed immunofluores-
cence based approaches to investigate levels of major components of the force transduction apparatus in specific 
muscle fibre types in a semi-quantitative manner24,26. Results from this approach mirror differences in ECM 
composition in WT and Mstn−/− muscles that we previously reported using a more laborious electron micros-
copy approach16. Interestingly, while qPCR detected similar differences at the transcriptional level, findings from 
immuno-blotting of muscle proteins did not concord our electron microscopy and semi-quantitative immuno-
fluorescence measurements. It is important to recognise that microscopy studies concentrated on components 
specifically at the plasma membrane. In contrast Western blot analyses were performed on total muscle lysates. 
The lack of correlation between the protein levels at the sarcolemma and total protein content suggests that the 
mechanism responsible for trafficking plays a major role in the assembly of the DGC. Furthermore, these results 
may have relevance in assessing the efficacy of therapies for diseases related to DGC proteins. Our results suggest 
Figure 3. ß-Dystroglycan profiles in WT, Mstn−/− and Mstn−/−/ErrγTg/+ mouse muscle. (A) Immunofluorescence 
profile of ß-Dystroglycan in relation to MHC fibre type. MHCIIB expression in red. Representative MHCIIB− 
indicated by yellow stars and MHCIIB+ fibres by white stars. Note higher of ß-Dystroglycan levels in all genotypes 
between MHCIIB− (yellow arrows) compared to MHCIIB+ (white arrows). (B) Expression of ß-Dystroglycan 
quantified by intensity by setting standard value of 1 for the level between MHCIIB− fibres from WT mice. (C) 
ß-Dystroglycan expression quantification in terms of thickness domain. n = 30 from each cohort. *p < 0.05, 
**p < 0.01, and ***p < 0.001. Statistical analysis performed by one-way ANOVA followed by Bonferroni 
correction of multiple comparisons.
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that total muscle protein content may not be a good metric for efficacy as it is possible to have high overall levels 
of DGC components without them localising to the sarcolemma. Indeed many studies now use proper localisa-
tion of DGC to the sarcolemma as a measure of therapy efficacy27. Furthermore, it highlights that a better under-
standing of the mechanism responsible for DGC translocation to the sarcolemma could be exploited to increase 
the efficacy of dystrophin restoration-based therapies.
Our previous work has shown that muscle from Mstn−/− mice contained less collagen than WT. Those find-
ings could be explained either by the constraints placed on a cell through the limited functional capacity of the 
nucleus (e.g. the karyoplasmatic hypothesis of Strassburger and Hertwig amongst other28,29) or as a consequence 
of the development of muscle with rapid contraction characteristics underpinned by glycolytic metabolism fol-
lowing gene deletion30. In the former, the muscle fibre would undergo enlargement without a commensurate 
increase in the amount of collagen. In the latter, fast contracting muscle fibres should always be bestowed with 
lower levels of ECM so to decrease the proportion of energy stored in the connective tissue, making more availa-
ble for work30. Indeed, it has been shown by a number of investigators that fast muscle has less ECM than slow17,31. 
However, in our previous study we were unable to define the influence of fibre type on collagen levels and it was 
limited to only extracellular components of the force transduction apparatus. Here we show that unrelatedly to 
genotype, MHCIIB− fibres have greater amounts of DGC than MHCIIB+ fibres. Secondly, we show that inducing 
oxidative phosphorylation in hypertrophic fibres alters the expression of sarcolemmal DGC proteins. It is critical 
to keep in mind we are detecting effects that are not linked to fibre type switching. These findings highlight an 
original and unforeseen result. According to the work of Kovanen and colleagues17,30,31, one would predict that 
all MHCII myofibres, irrespective of genotypes, should contain similar levels of DGC proteins. We show that this 
prediction is violated. Our work points to the fact that metabolic programme of muscle has primacy over MHCII 
expression with regards to DGC expression.
The examination of both the intercellular and extracellular components of the DGC and the ECM reveals a 
possible influence of the muscle metabolic programme on both the muscle fibre and their fibroblasts, major pro-
ducers of collagen32–34. The important feature here is that metabolic programme must harmonises the production 
Figure 4. α-Sarcoglycan profiles in WT, Mstn−/− and Mstn−/−/ErrγTg/+ mouse muscle. (A) Immunofluorescence 
profile of α-Sarcoglycan in relation to MHC fibre type. MHCIIB expression shown in red. Representative 
MHCIIB− fibres indicated by yellow stars and MHCIIB+ fibres by white stars. Note higher levels of α-Sarcoglycan 
in all genotypes between MHCIIB− (yellow arrows) compared to MHCIIB+ (white arrows). (B) Expression 
of α-Sarcoglycan quantified by intensity by setting standard value of 1 for the level between MHCIIB− fibres 
from WT mice. (C) α-Sarcoglycan expression quantification in terms of thick domain. n = 30 from each 
cohort. *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical analysis performed by one-way ANOVA followed by 
Bonferroni correction of multiple comparisons.
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of DGC and ECM from these two cellular sources in keeping with the muscle (oxidative/glycolytic) phenotype. 
This study reveals a fascinating relationship between muscle and fibroblasts. Previous work has shown that 
myostatin is an inhibitor of muscle hypertrophy14 but promotes muscle fibroblast proliferation35. Therefore, it 
would be predicted that in the absence of myostatin, muscle would be hypertrophic and invested with less ECM 
due to the decreased number of collagen secreting fibroblasts, which is in fact what is observed. However, the 
remodelling of Mstn−/− muscle following Errγ expression demonstrates that oxidative metabolism could over-
come the effects of the absence of Mstn on fibroblasts.
Our understanding of the aetiology of ECM in undamaged muscle is poor compared to myogenic or neuro-
genic development2. ECM components are produced by numerous cells in muscle including myogenic cells36, 
satellite cells37 and Schwann cells38 but it is believed that it is the fibroblast population that not only produce most 
of the ECM but also organise it into a functional unit39. However, to our knowledge there is no study describing 
the role of factors that control the formation of ECM and which are produced by myofibres that are dependent 
Figure 5. Laminin profiles in WT, Mstn−/− and Mstn−/−/ErrγTg/+ mouse muscle. (A) Immunofluorescence 
profile of laminin in relation to MHC fibre type. MHCIIB expression in red. Representative MHCIIB− fibres 
indicated by yellow stars and MHCIIB+ fibres by white stars Note higher levels of Laminin in all genotypes 
between MHCIIB− (yellow arrows) compared to MHCIIB+ (white arrows). (B) Expression of Laminin 
quantified by intensity by setting standard value of 1 for the level between MHCIIB− fibres from WT mice. 
(C) Laminin expression quantification in terms of thick domain. (D) Graphic presentation of DGC and 
abundance revealed in this study. Dark shading represents increased levels detected at sarcolemma through 
immunofluorescence compared to lighter shading. n = 30 from each cohort. *p < 0.05, **p < 0.01, and 
***p < 0.001. Statistical analysis performed by one-way ANOVA followed by Bonferroni correction of multiple 
comparisons.
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on metabolic programmes. In other systems, for example the skin, it is known that overly active oxidative pro-
gramme result in the remodelling of the ECM through the secretion of metallomatrix proteases40. We clearly 
show that metabolic properties of muscle fibres influence ECM production and suggest that the allelic series used 
in this study could be a means of investigating this topic. In future we intend to isolate single muscle fibres from 
mice used in this investigation and using a combination of transcriptome and bio-informatic approaches, identify 
pathways and (secreted) molecules that originate from myogenic cells that regulate ECM synthesis in fibroblasts
Our work shows that endomysial ECM is regulated by the metabolic programme of the muscle fibre. We pro-
pose that increasing the quantity of the DGC and EMC in fibres that are prone to contraction mediated damage 
(fast fibres) could be of clinical value. Herein we suggest that increasing the oxidative properties of fast fibres in 
DMD will result in more connective tissue that may translate into greater resilience to contraction mediated dam-
age. We are nevertheless mindful that any intervention should only increase endomysial ECM and not promote 
fibrosis.
Our study using Mstn mutation reveals an interesting feature related to the composition of the DGC. Most 
DGC models are depicted as having equimolar contribution of each component to this complex (e.g.41). In line 
with our previous report of multiple and independent dystroglycan and dystrophin complexes42, we demonstrate 
here that there can be variability in DGC complex at the sarcolemma. Here, we detected increased levels of βSG 
and δSG in Mstn−/− fibres compared to other DGC components (Fig. 6, Supplementary Fig. 7 and graphic in 
Fig. 5). The biological relevance of changes DGC complex stoichiometry in Mstn−/− mutant have yet to be estab-
lished. It is undoubtedly significant as many studies have shown that the sarcoglycan complex protects the muscle 
fibre from damage43. As each sarcoglycan has a unique property we suggest that there is a functional significance 
for altering the sarcoglycan content in hypertrophic fibres based on the findings showing that mutations in each 
sarcoglycan manifests in a specific disease (limb-girdle muscular dystrophy type (LGMD) 2D, 2E, 2C and 2F are 
caused by mutations in α, ß, γ, δ respectively7).
In summary our work that demonstrates that the DGC is a highly adaptable structure that responds to the 
metabolic nature of the muscle fibre. In future this approach will be extended to explore the relationship of 
Figure 6. ß-Sarcoglycan profiles in WT, Mstn−/− and Mstn−/−/ErrγTg/+ mouse muscle. (A) Immunofluorescence 
profile of ß-Sarcoglycan in relation to MHC fibre type. MHCIIB expression identified by bright red colouring. 
Representative MHCIIB− fibres indicated by yellow stars and MHCIIB+ fibres by white stars. Note higher levels 
of ß-Sarcoglycan in all genotypes between MHCIIB− (yellow arrows) compared to MHCIIB+ (white arrows). (B) 
Expression of ß-Sarcoglycan quantified by intensity by setting standard value of 1 for the level between MHCIIB− 
fibres from WT mice. (C) ß-Sarcoglycan expression quantification in terms of thick domain. n = 30 from each 
cohort. *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical analysis performed by one-way ANOVA followed by 
Bonferroni correction of multiple comparisons.
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changes in metabolic activity the muscular dystrophies and sarcopenia and the abundance of DGC and ECM 
components.
Methods
ethical approval. Experimental procedures were approved by the University of Reading Animal Care and 
Ethical Review Committee and were conducted under a project license from the United Kingdom Home Office 
in agreement with the Animals (Scientific Procedures) Act 1986. Animals were humanely sacrificed via Schedule 
1 killing between 8:00–13:00.
Animal maintenance. Healthy C57Bl/6 WT, Mstn−/−, Mstn−/−/ErrγTg/+ mice were bred and maintained in 
accordance to the Animals (Scientific Procedures) Act 1986 (UK) and approved by the University of Reading in 
the Biological Resource Unit of Reading University. Mice were housed under standard environmental conditions 
(20–22 °C, 12–12 hr light–dark cycle) and provided food and water ad libitum. We used male mice that were 4–5 
months old for this study. Specific experimental group consisted of 4–6 mice.
Immunohistochemistry. Muscles were dissected following cervical dislocation into PBS. Muscles were snap 
frozen on a bed of isopentane cooled by liquid nitrogen. Frozen muscles (EDL, Soleus and TA) were mounted for 
cryo-sectioning in Tissue Tech freezing medium (Jung). 10 µm cryosections were taken using a Bright Cryostat 
(Bright PLC UK) and placed onto glass microscope slides. Tissue sections were air dried for 30 minutes at room 
temperature (RT) and either used immediately or stored at −80 °C. Sections were washed three times PBS prior to 
immunohistochemistry staining. Object slides were treated with permeabilisation buffer (0.952 g Hepes, 0.260 g 
MgCl2, 0.584 g NaCl, 0.1 g Sodium azide, 20.54 g Sucrose and 1 ml Triton X-100 in 200 ml dH2O) for 15 minutes 
at RT, before the application of block wash buffer (PBS with 5% foetal calf serum (v/v), 0.05% Triton X-100) for 
30 minutes at RT.
Primary antibodies were diluted in wash buffer and incubated overnight at 4 °C. All secondary antibodies were 
diluted in wash buffer for minimum of 30 minutes (in dark) prior to their application onto the slides. Sections 
were then incubated for 1 hr in the dark at room temperature. Finally, slides were mounted in fluorescent mount-
ing medium, and myonuclei were visualised using (2.5 µg/ml) 4,6-diamidino-2-phenylindole (DAPI). List of all 
antibodies used is provided in the Supplementary Information File.
Western blot. Fresh muscles were homogenized in lysis buffer (4M Urea, 125 mM Tris pH 6.8, 4% (w/v) 
SDS, protease inhibitors). Protein content was quantified with the Pierce BCA Protein assay. 20 µg of protein was 
resolved using 3–8% (for dystrophin) or 4–12% (for all the other DGC proteins) gradient SDS-PAGE mini-gels 
(pre-made gels from Invitrogen), and thereafter electro-transferred to nitrocellulose membranes (Whatman). 
Figure 7. Molecular and Western blot profiling of Soleus ECM associated molecules. (A) qPCR profile of 
DPC associated genes in soleus muscles n = 4 muscle. (B) Western blot analysis of protein extracts from soleus 
muscles from 4 wild type, 6 Mstn−/− and 6 Mstn−/−/ErrγTg/+ mice. Membranes were probed for dystrophin and 
α-actinin, or cut into strips to allow simultaneous probing of α-DG/β-DG/β-SG/α-actinin. Membrane images 
were cropped for clarity, but full membranes are shown in Supplementary Fig. 8. Densitometric quantification 
of protein bands was performed on non-saturated images. Values were normalised to α-actinin and then 
expressed as a ratio to WT samples run on the same gel (see materials and methods for details). For statistical 
comparisons, a one-way ANOVA followed by pair-wise comparisons using the Bonferroni correction was 
performed. *p < 0.05, **p < 0.01, and ***p < 0.001.
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Membranes were stained with Ponceau Red S to visualise lanes, check the quality of the protein transfer, and 
mark the placement of molecular weight markers. For detection of dystrophin, the entire membrane was incu-
bated with a mixture of antibodies against dystrophin and against α-actinin (loading control). For detection of 
DGC proteins, membranes were cut at appropriate molecular weights to allow simultaneous probing of the same 
samples with different anti-DGC antibodies, as well as α-actinin. For β-DG and β-SG that have very similar 
molecular weights, the same membrane was probed sequentially taking advantage of the fact that the two anti-
bodies are raised in different species. The membrane strip was first probed with the rabbit polyclonal antibody to 
β-SG. After image acquisition, the same membrane strip was incubated overnight at 4 °C in 0.1% (w/v) Tween-20/
Tris buffered saline, then probed with the mouse monoclonal antibody to β-DG. α-actinin was used as a loading 
control because it is expressed only in muscle fibres allowing us to normalise expression of our DAPC proteins 
to the amount of muscle tissue present in each sample. All membranes were blocked in 5% skim milk in 0.1% 
(w/v) Tween-20/Tris buffered saline for one hour at room temperature. Membranes were incubated with appro-
priate primary antibodies overnight at 4 °C followed by three five-minute washes in 0.1% (w/v) Tween-20/Tris 
buffered saline at room temperature. Thereafter, membranes were incubated at RT with the appropriate horse-
radish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch). Protein bands were visualized 
using enhanced chemiluminescence reagents (BioRad). Signal was detected on a ChemiDoc MP Imaging System 
(BioRad) at an automated range of exposures ranging from 1–60 seconds. For densitometric analysis, the Image 
Lab software was used to quantify protein band intensities from non-saturated exposures. Signal intensities for 
the proteins of interest were normalized to α-actinin probed on the same membrane, on the same exact sam-
ples. Final results for Mstn−/− and Mstn−/−/ErrγTg/+ mice were expressed as a ratio to WT samples. Because we 
could not run all samples on one single gel, the full set of wild type samples (N = 4) were run on all gels to avoid 
comparisons between samples run on different gels. List of all antibodies used, is given in theSupplementary 
Information File together with citations of prior publications where the primary antibodies were characterised. 
Unprocessed images of most of the entire membranes used to generate Fig. 7b are shown in Supplementary Fig. 8 
as well as positive and negative controls that were performed to confirm the specificity of the anti-βSG antibody.
Quantitative pCR. Frozen soleus muscles were homogenised in TRIzol (Fisher) by a tissue homogen-
iser. RNA was isolated and purified in the RNAeasy Mini Kit (Quigen, Manchester, UK) following the manu-
facturer instructions. RNA concentrations were measured using the Nanodrop 2000 (Thermo Scientific). Total 
RNA (5 µg) was reverse-transcribed to cDNA with SuperScript II Reverse Transcriptse (Invitrogen) and ana-
lysed by quantitative real-time RT-PCR on a StepOne Plus cycler, using the Applied Biosystems SYBR-Green 
PCR Master Mix. Primers were designed using the software Primer Express 3.0 (Applied Biosystems). Relative 
expression was calculated using the ΔΔCt method with normalization to the reference genes cyclophilin-B and 
hypoxanthine-guanine phosphoribosyltransferase (HPRT). All primer sequences are listed in the Supplementary 
Information File.
Semi-quantification of Collagen and Dystrophin Glycoprotein Complex (DGC) protein levels 
by means of immunofluorescence. Signal intensity of protein of interest was measured as previously 
published24,25,44. For this study the membrane signal intensities of approximately 30 muscle fibres of MHC phe-
notype (IIB+ and IIB−) in all muscle sections (EDL, Soleus and TA) from WT, Mstn−/−, Mstn−/−/ErrγTg/+ mice 
were measured. 10 random fibres of a specific phenotype from a central region of each muscle (or portion) were 
counted from three mice. Fiji software was used to measure signal from an area of interest after images have been 
corrected for background to avoid regions of signal saturation. All images, including internal controls, were taken 
at the same exposure in line with non-saturatied levels from WT tissue. We ensured that all subsequent images 
never reached saturation. Relative levels of signal intensity were calculated from individual fibre measurements of 
the three cohorts normalised to MHCIIB− of WT muscles.
sarcolemma thickness measurement. Images taken at the same exposure were used to quantify the 
expression domain thick for the protein of interest. Expression domain thicknesses between approximately 30 
pairs of juxtapositioned fibres of the same MHC phenotypes (IIB−/IIB− and IIB+/IIB+) from EDL, Soleus and TA 
muscle sections originating from the three genetic cohorts were measured using Fiji software. Data was exported 
into an Excel spreadsheet.
Imaging and analysis. Zeiss AxioImager A1 microscope was used to examine immunofluorescent stained 
sections, and images were captured using an Axiocam digital camera with Zeiss Axiovision computer software 
version 4.8. Images were transferred to Photoshop for sizing and annotation and exported at TIFF flies.
statistical analysis. Data are presented as mean ± SE. Significant differences among groups were analysed 
by one-way analysis of variance (ANOVA) followed by Bonferroni correction for multiple comparison tests as 
appropriate. Statistical analysis was performed on GraphPad Prism software. Differences were considered statis-
tically significant at *p < 0.05, **p < 0.01 or ***p < 0.001.
Data Availability
All relevant data related to this manuscript are available from the authors upon reasonable request.
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